Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of recombinant prrsv virus-like particle and preparation method thereof

A recombinant baculovirus and virus-like technology, applied in the biological field, can solve the problems of late neutralizing antibody titer and virus titer decline, and achieve the effect of good immune protection, virus resistance and good immune protection effect.

Active Publication Date: 2022-05-06
NORTHWEST A & F UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And studies have shown (HP-PRRSV envelope protein 5 glycosylation site mutation and functional exploration), site-directed mutation of the amino acid of the A epitope has a certain impact on the replication of the virus, resulting in a decrease in the virus titer. Therefore, how to Reducing the antagonistic effect of epitope A on epitope B is an urgent technical problem to be solved in recombinant PRRSV virus-like particle vaccines. The inventors prepared immunogenic recombinant PRRSV virus-like particles (ZL201811114020.6) in 2018. However, in actual production, there is still the problem of late generation of neutralizing antibody titers, and there is still room for improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of recombinant prrsv virus-like particle and preparation method thereof
  • A kind of recombinant prrsv virus-like particle and preparation method thereof
  • A kind of recombinant prrsv virus-like particle and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Embodiment 1: Construction of recombinant baculovirus Ac-PRRSVGP5-M

[0031] (1) Synthesis of PRRSV GP5 and M gene sequences:

[0032] Based on the sequence of PRRSV-SD16 strain (Genbank Accession No: JX087437.1), after artificial modification, the PRRSV GP5-M gene whose gene sequence is shown in SEQ ID No: 1 was obtained, and sent to Gene Synthesis Company for gene sequence synthesis , and set Bam H I and Hind III restriction sites at the 5' end and 3' end, respectively, to obtain insert fragments.

[0033] (2) Construction and identification of recombinant transfer vector:

[0034] The plasmid containing the target gene sequence GP5-M and the vector pBAC-5 (provided by Shaanxi Nuowei Lihua Biotechnology Co., Ltd., with a GFP marker gene on the vector, which can be used for fluorescence detection, see ZL201811114020.6) were subjected to Bam H I and Hind Ⅲ double enzyme digestion, after recovery and purification, use T4 ligase to perform ligation reaction, chemically ...

Embodiment 2

[0056] (1) Preparation of recombinant PRRSV virus-like particle vaccine:

[0057] The recombinant baculovirus Ac-PRRSV GP5-M prepared in Example 1 was inoculated into healthy sf9 cells at a ratio of 10%. After culturing at 27°C for 4-5 days, the cells and supernatant were collected by repeated freezing and thawing. After centrifuging for 20 minutes, collect the supernatant, then use the ammonium sulfate precipitation method to precipitate the target protein, resuspend the protein solution for 36-48 hours with binary ethyleneimine (BEI), and then use an equal amount of sodium thiosulfate Neutralize, and finally mix and emulsify the vaccine with Seppic ISA 206 adjuvant, and store it at 2-8°C for use.

[0058] In the vaccine preparation process, after the recombinant baculoviruses of Example 1 of the present invention, control group 1, control group 2 and control group 3 were cultured, they were all adjusted to a virus titer of 10 5 TCID 50 / ml, and then continue with subsequent ...

Embodiment 3

[0072] Example 3: Antibody ups and downs of vaccine immunized piglets

[0073] (1) The recombinant PRRSV virus-like particle vaccine and the vaccine of the control group 2 were prepared according to the method of Example 2, and the vaccine sample of the control group 3 (prepared by the invention patent ZL201811114020.6 was provided by Shaanxi Nuowei Lihua Biotechnology Co., Ltd. vaccine).

[0074] (2) Screen 10 one-month-old healthy piglets with double-negative PRRSV antigen and antibody, among which 1 piglet was randomly selected as the blank control group, and the remaining 9 piglets were randomly divided into 3 groups, 3 piglets in each group. The first group is immunized with the Ac-PRRSV GP5-M vaccine of the present invention (the amino acid sequence is shown in SEQ ID No: 2), the second group is immunized with the control group 2 vaccine (the amino acid sequence is shown in SEQ ID No: 6), and the third group Immune the vaccine of control group 3 (the vaccine prepared by...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention obtains a recombinant baculovirus capable of efficient replication by modifying the GP5-M protein, and its culture titer is relatively higher, and the vaccine is further prepared by utilizing the virus-like particle similar to the prepared PRRSV virion, and the vaccine Higher titers of neutralizing antibodies can be produced, and the anti-inflation rule of immunized piglets shows that the vaccine of the present invention can stimulate the body to produce high-concentration antibodies earlier, and can stimulate the body to produce higher average levels of antibodies after the second immunization. Antibody titers for better immune protection.

Description

Technical field: [0001] The invention belongs to the field of biotechnology, and relates to a recombinant PRRSV virus-like particle and a preparation method thereof. Background technique: [0002] Porcine reproductive and respiratory syndrome (Porcine reproductive and respiratory syndrome, PRRS), also known as "blue ear disease", its pathogen is porcine reproductive and respiratory syndrome virus (Porcine reproductive and respiratory syndrome virus, PRRSV), which mainly causes reproductive problems in pregnant sows. Obstacles and respiratory disorders in piglets, usually manifested as coughing and dyspnea in piglets, premature birth, abortion or even stillbirth in sows. Since it was discovered in North America in the late 1980s, the worldwide prevalence and several outbreaks of the disease have led to huge economic losses in the swine industry around the world. [0003] PRRSV belongs to the Arteriviridae family, which includes Simian Hemorrhagic Fever Virus, Equine Arteriti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/40C07K14/08C12N15/866C12N15/66A61K39/12A61P31/14
CPCC07K14/005C12N15/86A61K39/12A61P31/14C12N2770/10022C12N2770/10023C12N2770/10052C12N2770/10034C12N2710/14143C12N2800/105A61K2039/5258A61K2039/552
Inventor 陈瑞王晶钰南雨辰武春燕
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com